Skip to main content

Articles By Antoni Chan, MD, PhD

uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

By Antoni Chan, MD, PhD
01 December 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

Read Article
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

By Antoni Chan, MD, PhD
09 November 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

Read Article
Puzzle pieces

Axial spondyloarthritis with psoriasis or psoriatic spondylitis

By Antoni Chan, MD, PhD
08 November 2021

PsA commonly affects peripheral joints. In up to a quarter of PsA patients, the spine may be involved and this is known as psoriatic spondylitis (PsSpA). An important research question is whether PsSpA and Axial Spondyloarthritis (AxSpA) with psoriasis are separate conditions or not. 

Read Article
journal book learning study meeting notes

Excited About ACR Convergence 2020

By Antoni Chan, MD, PhD
06 November 2020

I always think of why I attend the ACR: to gain new information and knowledge and bring it back to my clinic for my patients. Here's what I'm looking forward to this year.

Read Article
Xeljanz4.jpg

Spondyloarthritis at ACR Convergence 2020

By Antoni Chan, MD, PhD
05 November 2020

There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting. 

Read Article
fitness-3448864_640.jpg

New Treatments in Axial SpA from #ACR2019

By Antoni Chan, MD, PhD
18 November 2019

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.

Read Article
×